CTLA-4Ig: Uses and Future Directions

Author(s): Moshe Ben-Shoshan.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 3 , Issue 2 , 2009

Submit Manuscript
Submit Proposal

Abstract:

Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family. Blocking CD28 interaction with its ligands through the use of CTLA-4Ig might contribute to better control of dysregulated immune response processes. The ligands binding to CTLA-4 are the B7 family members, B7-1 (CD80) and B7-2 (CD86). CTLA-4Ig is now a Food and Drug Administration-approved drug for use treating patients with Rheumatoid arthritis (RA) but its use is explored also in other autoimmune diseases, transplantation as well as allergic diseases. Patents related to CTLA-4 function as well as possible clinical applications are discussed in this paper.

Keywords: CTLA-4, CD-152, CTLA-4Ig, abatacept

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 3
ISSUE: 2
Year: 2009
Page: [132 - 142]
Pages: 11
DOI: 10.2174/187221309788489760
Price: $58

Article Metrics

PDF: 5